Latest Update: As of September 7, 2026, the most significant recent development in Empower Pharmacy litigation came on April 29, 2026, when a federal judge in the Southern District of Texas dismissed part of Eli Lilly’s lawsuit against Empower over compounded tirzepatide products. U.S. District Judge Sim Lake threw out the federal trademark claims and Texas unfair competition claims, while allowing unfair competition allegations under other states’ laws to move forward. The ruling addressed Eli Lilly’s marketing-related claims against Empower rather than the separate track of patient injury lawsuits, which remain active with no trial date set. No global settlement or MDL consolidation has been confirmed since this ruling.
Last updated: September 2026
The Empower Pharmacy lawsuit involves claims from patients who say they were harmed by improperly compounded medications. As of 2026, lawsuits target the Houston-based pharmacy for FDA violations, contamination issues, and the sale of compounded GLP-1 drugs like semaglutide.
If you used an Empower Pharmacy product and experienced side effects, you might have legal options. This article breaks down what’s happening with the lawsuits, who qualifies, potential settlement amounts, and how to file.
Here’s something most people don’t realize: Empower Pharmacy was one of the largest 503B compounding facilities in the country, processing millions of prescriptions annually. That scale made the FDA’s findings even more alarming.
You’ll find everything you need right here, from the latest 2026 case updates to filing deadlines and expected payouts.
Empower Pharmacy Lawsuit
The Empower Pharmacy lawsuit refers to legal claims filed by patients who received compounded medications from Empower Pharmacy and suffered adverse health effects. These lawsuits allege the pharmacy sold drugs that were contaminated, improperly formulated, or not tested to FDA standards.
Empower Pharmacy is headquartered in Houston, Texas. It operates as a 503B outsourcing facility, which means it compounds large batches of drugs without individual patient prescriptions. That’s a big deal because 503B pharmacies are supposed to follow strict FDA manufacturing rules.
The core of these lawsuits boils down to one question: did Empower cut corners on safety? Plaintiffs say yes. They point to FDA inspection reports, warning letters, and documented manufacturing failures.
| Detail | Info |
|---|---|
| Defendant | Empower Pharmacy, Houston, TX |
| Facility Type | 503B Outsourcing Facility |
| Primary Allegations | Contamination, cGMP violations, improper drug formulation |
| Key Products at Issue | Compounded semaglutide, tirzepatide, sterile injectables |
| Court Jurisdiction | Southern District of Texas and state courts |
Multiple law firms across the country are now reviewing cases. The lawsuit encompasses individual injury claims and broader product liability actions. Patients who suffered infections, allergic reactions, or drug potency issues are among those filing.
Think of a 503B pharmacy like a mini drug manufacturer. They’re held to higher standards than your neighborhood compounding pharmacy. When those standards slip, the consequences can affect thousands of patients at once.
Empower Pharmacy Lawsuit Update 2026
As of 2026, the Empower Pharmacy lawsuit continues to gain momentum. New plaintiffs are joining existing cases, and attorneys are actively building claims around the pharmacy’s compounded GLP-1 products.
The FDA took significant enforcement actions against Empower Pharmacy throughout 2024 and 2025. Warning letters cited failures in sterility testing, endotoxin screening, and potency verification. These enforcement records form the backbone of current litigation.
In early 2026, several law firms announced they are investigating whether a multidistrict litigation (MDL) consolidation is appropriate. MDL status would combine federal cases into one court for pretrial proceedings. That hasn’t been granted yet, but the volume of claims makes it a real possibility.
- January 2026: Additional plaintiffs filed individual injury lawsuits in Texas state court.
- February 2026: FDA released follow-up inspection data showing ongoing compliance concerns.
- March 2026: At least three major plaintiff firms announced case reviews for Empower GLP-1 claims.
- Q2 2026: MDL petition discussions are underway among plaintiff steering committees.
The legal situation is still developing. No settlement has been finalized. But the pace of filings suggests this litigation could become one of the larger compounding pharmacy cases in recent years.
Attorneys say the strongest claims involve patients who can document their purchase from Empower, the specific product received, and the adverse reaction they experienced. Medical records linking the reaction to the compounded drug are critical.
Empower Pharmacy Class Action Lawsuit
A class action lawsuit against Empower Pharmacy has not been formally certified as of mid-2026. However, the groundwork for class action status is being laid by plaintiff attorneys in multiple states.
Class action certification requires proving that a large group of people suffered similar harm from the same company’s conduct. In this case, the alleged conduct is the sale of improperly compounded medications. Thousands of patients across the U.S. received Empower products, which supports the numerosity requirement.
There’s a difference between a class action and mass tort, and it matters here. In a class action, everyone gets the same outcome. In a mass tort, each case is evaluated individually. Right now, most Empower claims are structured as individual or mass tort cases.
| Legal Structure | How It Works | Empower Status (2026) |
|---|---|---|
| Class Action | One lawsuit represents all affected people | Not yet certified |
| Mass Tort | Individual cases grouped for efficiency | Active filings |
| MDL (Multidistrict Litigation) | Federal cases consolidated for pretrial | Under discussion |
| Individual Lawsuit | One plaintiff sues independently | Active in TX courts |
Some attorneys believe a class action may eventually form around economic claims. For example, patients who overpaid for compounded drugs that were substandard could form a consumer fraud class.
Injury claims, on the other hand, will likely stay as individual or mass tort cases. That’s because each patient’s injuries, medical history, and damages are different.
Key Takeaway: The Empower Pharmacy lawsuit is active and growing in 2026, with mass tort filings leading the way while class action certification remains under review.
Empower Pharmacy Semaglutide Lawsuit
The Empower Pharmacy semaglutide lawsuit focuses on compounded versions of semaglutide sold by Empower. Semaglutide is the active ingredient in brand-name drugs like Ozempic and Wegovy, used for diabetes and weight loss.
Empower was one of the biggest compounding pharmacies selling semaglutide during the drug shortage period. When the FDA declared semaglutide in shortage, compounding pharmacies like Empower could legally produce their own versions. The problem? Plaintiffs allege Empower’s compounded semaglutide wasn’t made to the same safety standards.
The FDA removed semaglutide from its drug shortage list in February 2024 for certain formulations. That removal triggered a legal battle over whether compounders like Empower could continue selling their versions. Empower fought to keep selling and filed its own lawsuits against the FDA.
Here’s where it gets complicated for patients. Some people bought compounded semaglutide from Empower during and after the shortage period. If those products were subpotent, contaminated, or improperly stored, patients may have received a drug that didn’t work as intended or caused harm.
- Allegations include incorrect dosage concentrations
- Some patients report injection site infections
- Others claim the drug simply didn’t contain the right amount of semaglutide
- FDA testing found potency failures in compounded GLP-1 products across the industry
Lawsuits specifically name Empower’s semaglutide products as defective. If you received compounded semaglutide from Empower and experienced problems, this is the claim category most attorneys are focused on.
Empower Pharmacy FDA Warning
The FDA warning directed at Empower Pharmacy is one of the strongest pieces of evidence in ongoing lawsuits. FDA warning letters are official notices that a company is violating federal law, and they carry serious weight in court.
The FDA issued a formal warning letter to Empower Pharmacy citing multiple violations of current Good Manufacturing Practices (cGMP). These violations included failures in sterility assurance, inadequate environmental monitoring, and problems with endotoxin testing for injectable drugs.
Injectable drugs that aren’t properly tested for sterility can cause life-threatening infections. Endotoxin contamination can trigger fever, organ failure, and sepsis. These aren’t theoretical risks. They’re documented medical emergencies.
| FDA Finding | What It Means for Patients |
|---|---|
| Sterility testing failures | Injections may contain bacteria |
| Endotoxin screening gaps | Risk of severe inflammatory reactions |
| Potency verification issues | Drug may be too strong or too weak |
| Environmental monitoring gaps | Manufacturing area may not be clean enough |
| Inadequate quality controls | Overall product safety not assured |
The FDA also conducted follow-up inspections. Reports from those inspections showed that some issues persisted even after the initial warning. In litigation, that pattern of repeated violations can support claims of negligence or willful disregard for patient safety.
Empower Pharmacy responded to the FDA warnings by disputing some findings and pledging corrective action on others. But in the eyes of plaintiff attorneys, the warning letters are a smoking gun.
Empower Pharmacy Settlement
No Empower Pharmacy settlement has been reached as of mid-2026. The litigation is still in its early-to-middle stages. But understanding how pharmaceutical settlements typically work can help set expectations.
Settlements in compounding pharmacy cases usually happen after significant discovery. Discovery is the phase where both sides exchange documents, take depositions, and review evidence. That process can take 12 to 24 months depending on complexity.
In similar compounding pharmacy lawsuits, settlements have ranged widely. The New England Compounding Center (NECC) case, which involved contaminated steroid injections that killed 76 people, resulted in a $200 million settlement fund. Empower’s case is different in scale, but the legal framework is comparable.
- No global settlement has been proposed yet
- Individual settlements could begin once bellwether cases are resolved
- Bellwether trials are test cases used to gauge jury reactions
- Settlement negotiations typically start after bellwether verdicts
If you’re waiting for a check, it won’t come quickly. Pharmaceutical litigation moves slowly. But the fact that multiple firms are investing resources into Empower claims signals that attorneys believe there’s real value here.
One thing to watch: if MDL status is granted, a settlement could follow within 18 to 36 months of consolidation. Without MDL, individual cases may settle at different times and for different amounts.
Key Takeaway: No Empower Pharmacy settlement exists yet, but the case trajectory and attorney investment suggest meaningful compensation is possible for qualified claimants.
Empower Pharmacy Settlement Amounts
Predicting Empower Pharmacy settlement amounts requires looking at comparable cases and the types of injuries involved. While no official payout numbers exist yet, legal analysts have offered preliminary ranges.
Settlement amounts in pharmaceutical injury cases depend on several factors. The severity of injury is the biggest one. A patient who was hospitalized for a week with a drug-related infection will receive far more than someone who experienced mild side effects.
Here’s a rough framework based on similar compounding pharmacy cases:
| Injury Level | Estimated Range | Examples |
|---|---|---|
| Mild adverse effects | $5,000 to $25,000 | Nausea, rash, injection site pain |
| Moderate injuries | $25,000 to $150,000 | Infection requiring treatment, allergic reaction |
| Severe injuries | $150,000 to $500,000 | Hospitalization, organ damage, sepsis |
| Catastrophic or fatal | $500,000 to $2,000,000+ | Death, permanent disability, long-term organ failure |
| Economic-only claims | $500 to $5,000 | Overpayment for substandard product |
These are estimates based on industry patterns, not guarantees. Every case is different. The strength of your medical documentation plays a huge role in determining your potential payout.
Attorneys typically take these cases on contingency. That means you pay nothing upfront. The attorney’s fee is usually 33% to 40% of your settlement or verdict. Some firms also deduct case expenses from the recovery.
If your injury was minor, an economic claim for the cost of the drug itself might be your best option. For serious injuries, individual lawsuits tend to yield higher payouts than class action distributions.
Empower Pharmacy Lawsuit Eligibility
Eligibility for the Empower Pharmacy lawsuit depends on a few specific factors. You generally qualify if you received a compounded medication from Empower Pharmacy and experienced an adverse health effect.
The first thing attorneys look for is proof of purchase. Did you buy a compounded drug from Empower directly, or through a telehealth provider or clinic that sourced from Empower? Either scenario can qualify you.
Next, they look at injury. You need to show that you experienced a negative health outcome connected to the Empower product. That connection doesn’t have to be airtight at the filing stage, but you’ll need medical records eventually.
You may qualify if:
- You received compounded semaglutide or tirzepatide from Empower
- You experienced infection, allergic reaction, or unexpected side effects
- You were hospitalized or needed medical treatment after using an Empower product
- You received a compounded injectable from Empower that was later recalled or flagged by the FDA
- You paid for a product that turned out to be subpotent or contaminated
You likely do not qualify if:
- You used FDA-approved brand-name Ozempic, Wegovy, or Mounjaro (not compounded versions)
- You had side effects that are normal and expected from the drug type
- You have no documentation of purchase or medical treatment
Documentation is king in these cases. Save pharmacy receipts, prescription records, and any communication with your prescriber. Medical records showing treatment for adverse reactions are the most valuable evidence you can have.
How to File an Empower Pharmacy Lawsuit
Filing an Empower Pharmacy lawsuit starts with contacting a plaintiff attorney who handles pharmaceutical injury cases. Most firms offer free case evaluations, and you won’t pay anything unless you win.
Here’s the step-by-step process:
Step 1: Gather your records. Collect pharmacy receipts, prescription details, medical records showing adverse effects, and any correspondence with Empower or your prescriber.
Step 2: Contact a law firm. Look for firms that specialize in pharmaceutical litigation, mass torts, or product liability. During the initial consultation, they’ll ask about your injury, your timeline, and your documentation.
Step 3: Case evaluation. The attorney reviews your information and determines whether your claim has legal merit. This usually takes a few days to a few weeks.
Step 4: Filing the complaint. If accepted, the firm files a lawsuit on your behalf. You’ll be named as the plaintiff, and Empower Pharmacy will be served as the defendant.
Step 5: Discovery and litigation. The case enters the discovery phase, where evidence is exchanged. This can take months.
| Filing Step | Timeline | What You Need |
|---|---|---|
| Initial consultation | 1 to 2 weeks | Basic injury info |
| Case evaluation | 2 to 4 weeks | Medical records, purchase proof |
| Complaint filed | 1 to 3 months after evaluation | Attorney handles this |
| Discovery phase | 6 to 18 months | Ongoing document requests |
| Settlement or trial | 12 to 36 months from filing | Patience |
Most patients never step inside a courtroom. The vast majority of pharmaceutical cases settle before trial. Your attorney handles the heavy lifting.
Key Takeaway: Filing an Empower Pharmacy lawsuit requires proof of purchase and documented injury; most firms take these cases on contingency with no upfront cost.
Empower Pharmacy Recall
Empower Pharmacy recalls have been issued for specific compounded products that failed quality testing. These recalls are a central piece of evidence in the broader litigation.
When the FDA finds that a compounded drug doesn’t meet safety standards, it can request a voluntary recall. If the pharmacy refuses, the FDA can pursue mandatory recall or seizure. In Empower’s case, certain sterile injectable products were recalled due to concerns about sterility and potency.
Recalls don’t always make front-page news. Many patients who received recalled products were never notified directly. That’s a problem. If you used a product that was later pulled from the market, you might not even know your medication was flagged.
- Recalled products include certain sterile injectables
- Issues cited: failed sterility testing, potency deviations
- FDA enforcement actions accompanied several recalls
- Some recalls were voluntary; others followed FDA pressure
Check the FDA’s recall database for specific lot numbers. If your medication matches a recalled lot, that significantly strengthens your legal claim.
The recall history also matters because it shows a pattern. A single recall could be an isolated manufacturing error. Multiple recalls suggest a systemic quality control problem. Attorneys arguing negligence will point to that pattern.
Empower Pharmacy Compounding Violations
Compounding violations at Empower Pharmacy form the legal foundation of most claims. These violations relate to how the pharmacy manufactured, tested, and distributed its compounded drugs.
Compounding pharmacies are required to follow specific rules depending on their designation. As a 503B outsourcing facility, Empower was required to comply with current Good Manufacturing Practices, or cGMP. These are the same rules that apply to major drug manufacturers.
The violations found during FDA inspections included:
- Failure to establish adequate written procedures for production and process controls
- Insufficient testing of finished drug products before distribution
- Gaps in environmental monitoring of cleanroom facilities
- Incomplete batch records that made it impossible to trace problems
- Deviations in endotoxin testing protocols for sterile injectables
Think of cGMP violations like building code violations in a house. One minor issue might not cause a collapse. But when inspectors find multiple structural problems, the whole building is suspect. That’s the situation with Empower.
These violations are damaging in court because they show the company knew, or should have known, that its products might not be safe. That knowledge is what separates a simple mistake from actionable negligence.
| Violation Type | Risk to Patients | Legal Significance |
|---|---|---|
| Sterility failures | Infection, sepsis | Direct evidence of defective product |
| Potency deviations | Ineffective treatment, overdose risk | Proof of manufacturing negligence |
| Record-keeping gaps | Unknown product history | Shows inadequate quality controls |
| Environmental monitoring failures | Contamination risk | Supports claims of unsafe conditions |
Empower Pharmacy Contamination Claims
Contamination claims against Empower Pharmacy allege that patients received drugs tainted with bacteria, endotoxins, or foreign particles. These are some of the most serious allegations in the lawsuit.
Contamination in compounded drugs is not a theoretical concern. The most infamous case in the industry, the NECC fungal meningitis outbreak in 2012, killed 76 people and sickened hundreds more. That case put compounding pharmacy safety under a national spotlight.
Empower’s contamination issues are different in nature but follow a similar pattern of quality control failures. FDA inspections revealed problems with how Empower tested its products for microbial contamination before releasing them to patients.
Patients who received contaminated injectable drugs may have experienced:
- Fever and chills shortly after injection
- Injection site infections (redness, swelling, abscess formation)
- Systemic infections requiring hospitalization
- Sepsis or blood infections in severe cases
- Unusual reactions not consistent with the prescribed medication
The challenge with contamination claims is proving causation. You need medical records showing your adverse reaction, the specific Empower product you received, and ideally a culture or lab result identifying the contaminant. That’s a high bar, but attorneys experienced in pharmaceutical cases know how to build these arguments.
Some contamination claims may be strengthened by FDA testing data. If the FDA tested products from the same batch you received and found contamination, that’s powerful evidence you don’t even need to generate yourself.
Key Takeaway: Contamination claims against Empower are among the strongest in the litigation, especially for patients who can link specific recalled batches to their adverse health events.
Empower Pharmacy GLP-1 Lawsuit
The Empower Pharmacy GLP-1 lawsuit centers on compounded versions of popular weight loss and diabetes drugs. GLP-1 receptor agonists like semaglutide and tirzepatide became some of the most prescribed medications in the country, and demand far outpaced supply.
That shortage created a massive market for compounded alternatives. Empower Pharmacy became one of the dominant players, filling prescriptions for compounded GLP-1 injections that cost a fraction of brand-name prices. Patients paid anywhere from $100 to $400 per month for compounded versions versus $1,000+ for Ozempic or Wegovy.
The legal issue isn’t that compounding is inherently wrong. It’s that the compounded products allegedly didn’t meet safety and quality standards. Patients trusted that they were getting a reliable alternative to expensive brand-name drugs. Plaintiffs say that trust was broken.
| GLP-1 Drug | Brand Name | Manufacturer | Compounded by Empower? |
|---|---|---|---|
| Semaglutide | Ozempic, Wegovy | Novo Nordisk | Yes |
| Tirzepatide | Mounjaro, Zepbound | Eli Lilly | Yes |
The FDA’s decision to remove these drugs from the shortage list is a critical legal turning point. Once a drug is no longer in shortage, compounding pharmacies lose their legal authority to make copies. Empower challenged these decisions in court, but the broader patient injury claims remain separate from that regulatory fight.
If you took a compounded GLP-1 drug from Empower and it didn’t work, made you sick, or caused unexpected side effects, the GLP-1 lawsuit track is where your claim fits.
Empower Pharmacy Tirzepatide Legal Action
Tirzepatide legal action against Empower Pharmacy mirrors the semaglutide claims but involves a different drug. Tirzepatide is the active ingredient in Mounjaro and Zepbound, manufactured by Eli Lilly.
Eli Lilly aggressively fought against compounding pharmacies producing tirzepatide. The company argued that tirzepatide was never actually in shortage and that compounders had no legal right to copy it. The FDA sided with Eli Lilly in late 2024 when it declared tirzepatide was no longer in shortage.
Empower Pharmacy sued the FDA over this determination. That legal battle is separate from patient injury claims, but it matters because it created confusion. During the regulatory fight, patients continued receiving compounded tirzepatide. Some of those products may have been manufactured under conditions that didn’t meet cGMP standards.
Patient claims related to compounded tirzepatide include:
- Products that didn’t produce expected therapeutic effects
- Adverse reactions not seen with brand-name tirzepatide
- Dosing inconsistencies between batches
- Injection site complications including infections and abscesses
The tirzepatide claims carry an extra layer of complexity. Because the drug’s shortage status was disputed, there’s a question about whether Empower even had the legal right to compound it during certain periods. If they didn’t, selling it could constitute an additional violation beyond manufacturing defects.
Patients who used Empower’s compounded tirzepatide should keep all pharmacy records, medical documentation, and communication with their healthcare providers. These records are essential for any legal claim.
Empower Pharmacy Side Effects Lawsuit
The side effects lawsuit against Empower Pharmacy covers a range of adverse reactions reported by patients. These go beyond the normal, expected side effects of GLP-1 drugs and point to problems with the compounded products themselves.
Normal side effects of semaglutide and tirzepatide include nausea, diarrhea, and decreased appetite. Those are well-documented and expected. The side effects driving lawsuits are different. They suggest something was wrong with the drug itself, not just the drug’s inherent properties.
Abnormal side effects reported in Empower claims:
- Severe injection site reactions (large abscesses, cellulitis)
- Fever and chills within hours of injection
- Anaphylactic or severe allergic reactions
- Dramatic blood sugar crashes inconsistent with dosing
- Symptoms of infection (sepsis markers, elevated white blood cell count)
- No therapeutic effect at all, suggesting the drug had little or no active ingredient
The distinction between expected and unexpected side effects is critical. If you experienced standard GLP-1 side effects like mild nausea, that’s probably not the basis for a lawsuit. But if you ended up in the emergency room with a raging infection after an injection, that’s a different story.
| Side Effect Type | Normal for GLP-1? | May Support Lawsuit? |
|---|---|---|
| Mild nausea | Yes | Unlikely |
| Injection site redness | Sometimes | Depends on severity |
| Severe abscess at injection site | No | Yes |
| Fever, chills after injection | No | Yes |
| Sepsis or systemic infection | No | Yes |
| No therapeutic effect | Unusual | Possibly (potency issue) |
Document everything. Photos of injection site reactions, ER visit records, lab results, and prescriptions are all valuable evidence.
Key Takeaway: Side effects lawsuits focus on reactions that go beyond normal GLP-1 drug responses and point to contamination, incorrect potency, or manufacturing defects in Empower’s compounded products.
Empower Pharmacy Lawsuit Deadline
The deadline to file an Empower Pharmacy lawsuit depends on your state’s statute of limitations. There is no single federal deadline for all claims.
Statutes of limitations for pharmaceutical injury cases typically range from 1 to 6 years, depending on the state. Most states set the clock at 2 to 3 years from the date of injury or the date you discovered (or should have discovered) the connection between your injury and the drug.
| State | Statute of Limitations (Personal Injury) | Discovery Rule? |
|---|---|---|
| Texas | 2 years | Yes |
| California | 2 years | Yes |
| Florida | 2 years (changed from 4 in 2024) | Yes |
| New York | 3 years | Yes |
| Illinois | 2 years | Yes |
| Pennsylvania | 2 years | Yes |
| Ohio | 2 years | Yes |
The “discovery rule” is important. It means the clock doesn’t necessarily start when you took the drug. It starts when you knew or reasonably should have known that the drug caused your injury. If you just learned about the FDA warnings in 2026, you may still be within the filing window even if your injury occurred in 2023.
Don’t assume you’ve missed the deadline. Contact an attorney for a case-specific evaluation. Missing the statute of limitations by even one day can permanently bar your claim. That’s one area where waiting too long can cost you everything.
If you’re unsure about your timeline, err on the side of acting now. Filing sooner gives your attorney more time to build a strong case.
Is Empower Pharmacy Safe?
Whether Empower Pharmacy is safe depends on how you define safety, but the FDA’s findings raise serious red flags. As of 2026, Empower Pharmacy continues to operate, though under increased regulatory scrutiny.
The FDA’s inspection reports documented multiple violations of manufacturing standards. Those findings don’t automatically mean every product Empower makes is dangerous. But they do mean the systems designed to catch problems before products reach patients weren’t working properly.
Empower has publicly stated that it has implemented corrective actions in response to FDA findings. The company maintains that its products are safe and effective. But plaintiffs in the lawsuits argue that Empower’s corrective actions came too late and were insufficient.
Factors to consider:
- FDA warning letters are a serious indicator of safety concerns
- Not all Empower products have been recalled or flagged
- The pharmacy has challenged some FDA findings in court
- Regulatory oversight of 503B facilities has increased industry-wide since 2024
- Brand-name drugs (when available) undergo more rigorous testing
If you’re currently using a compounded medication from Empower, talk to your healthcare provider. They can help you weigh the risks and benefits and determine whether switching to a brand-name alternative makes sense.
The broader question of compounding pharmacy safety extends beyond Empower. The entire 503B industry has faced increased scrutiny. But Empower’s size and market presence make it a focal point.
Empower Pharmacy Patient Compensation
Patient compensation from Empower Pharmacy lawsuits will depend on the outcome of litigation. Right now, no compensation fund has been established, but the path to recovery is becoming clearer.
There are two main ways patients could receive compensation. The first is through individual lawsuit settlements or verdicts. The second is through a class action settlement fund, if a class is eventually certified.
Individual settlements tend to pay more because each case is evaluated on its own merits. A patient with severe injuries and strong documentation could receive significantly more than someone with minor complaints. Class action distributions, by contrast, spread a fixed amount across all class members.
What could your compensation cover?
- Medical expenses related to treating adverse drug reactions
- Hospital bills, including emergency room visits and inpatient stays
- Lost wages if your injury prevented you from working
- Pain and suffering damages
- Out-of-pocket costs for the compounded medication itself
- Future medical costs if your injury requires ongoing treatment
| Compensation Type | What It Covers | How It’s Calculated |
|---|---|---|
| Economic damages | Medical bills, lost wages, drug costs | Based on actual documented expenses |
| Non-economic damages | Pain, suffering, emotional distress | Jury determination or negotiated amount |
| Punitive damages | Punishment for egregious conduct | Rare but possible if negligence was willful |
To maximize your compensation, start building your file now. Every receipt, medical record, and pharmacy statement matters. Attorneys consistently say that clients with the best documentation get the best outcomes.
Don’t wait for a settlement announcement to act. By the time a settlement is public, the best-prepared claimants will be at the front of the line.
Key Takeaway: Patient compensation will vary widely based on injury severity and documentation quality; building a complete file now is the single most important step you can take.
Frequently Asked Questions
What is the Empower Pharmacy lawsuit about?
The Empower Pharmacy lawsuit involves claims that the pharmacy sold improperly compounded medications that harmed patients.
Allegations include contamination, potency errors, and violations of FDA manufacturing standards.
The lawsuits primarily target compounded GLP-1 drugs like semaglutide and tirzepatide.
Who qualifies for the Empower Pharmacy lawsuit in 2026?
You may qualify if you received a compounded medication from Empower and experienced adverse health effects.
Proof of purchase and medical records showing your reaction are the key requirements.
Both direct Empower customers and patients who received Empower products through telehealth providers can file.
How much money could I get from an Empower Pharmacy settlement?
Estimated payouts range from $5,000 to over $500,000 depending on injury severity.
Mild side effects may yield smaller economic claims, while hospitalizations and severe injuries could result in six-figure settlements.
No official settlement amounts have been announced as of 2026.
What is the deadline to file an Empower Pharmacy lawsuit?
Deadlines depend on your state’s statute of limitations, typically 2 to 3 years from the date of injury or discovery.
The discovery rule may extend your deadline if you only recently learned your injury was connected to the drug.
Contact an attorney immediately to confirm your specific filing window.
Is Empower Pharmacy still open and operating in 2026?
Yes, Empower Pharmacy remains operational as of 2026.
The company continues to compound and dispense medications under increased FDA oversight.
Ongoing lawsuits and regulatory actions have not resulted in a shutdown.
What You Should Do Right Now
The Empower Pharmacy lawsuit is real, it’s growing, and 2026 is a pivotal year. If you used compounded medications from Empower and something went wrong, your window to act is open.
Gather your records. Contact a pharmaceutical injury attorney. Get your case evaluated at no cost.
The strongest claims are built early, before memories fade and records get lost. Don’t sit on this one
